Abstract
A recent study, published in Nature, identifies the methylcytosine dioxygenase 2 (TET2) as an epigenetic modifier that is regulated in response to glucose availability and mechanistically links higher cancer susceptibility in patients with diabetes to high blood glucose levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
